NCT02935296

Integrated Treatment and Prevention for People Who Inject Drugs

Completed NA Last updated 1 April 2025

What this trial tests

NA trial testing Integrated Intervention in HIV Positive in 1,281 participants. Completed in 30 June 2018.

Timeline

4 February 2015

Primary endpoint
16 June 2017

30 June 2018

Quick facts

Lead sponsor	HIV Prevention Trials Network
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	1,281
Start date	4 February 2015
Primary completion	16 June 2017
Estimated completion	30 June 2018
Sites	3 locations across Indonesia, Vietnam, Ukraine

Drugs / interventions tested

• Integrated Intervention

Conditions studied

• HIV Positive — all drugs for HIV Positive →

Sponsor

HIV Prevention Trials Network

Who can join

Adults 18 to 45, any sex, with HIV Positive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the feasibility of a future trial that will assess whether an integrated intervention combining psychosocial counseling and supported referrals for antiretroviral therapy (ART) at any CD4 cell count and substance use treatment for HIV-infected people who inject drugs (PWID) will reduce HIV transmission to HIV-uninfected injection partners, as compared to routine care dictated by national guidelines for HIV-infected PWID.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study.
   Miller WC, Hoffman IF, Hanscom BS, Ha TV, et al · · 2018 · cited 74× · PMID 30191830 · DOI 10.1016/s0140-6736(18)31487-9
2. Use of Antiretroviral Drug Testing to Assess the Accuracy of Self-reported Data from HIV-Infected People Who Inject Drugs.
   Fogel JM, Zhang Y, Palumbo PJ, Guo X, et al · · 2019 · cited 15× · PMID 30600453 · DOI 10.1007/s10461-018-2379-8
3. Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis.
   Lancaster KE, Hoffman IF, Hanscom B, Ha TV, et al · · 2018 · cited 15× · PMID 30350406 · DOI 10.1002/jia2.25195
4. HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074.
   Palumbo PJ, Zhang Y, Fogel JM, Guo X, et al · · 2019 · cited 12× · PMID 31600343 · DOI 10.1371/journal.pone.0223829
5. Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study.
   Kiriazova T, Go VF, Hershow RB, Hamilton EL, et al · · 2020 · cited 10× · PMID 32998731 · DOI 10.1186/s12954-020-00415-x
6. Reported Participation Benefits in International HIV Prevention Research with People Who Inject Drugs.
   Sugarman J, Trumble I, Hamilton E, Sarasvita R, et al · · 2019 · cited 8× · PMID 31541541 · DOI 10.1002/eahr.500030
7. Phylogenetic Analysis of Human Immunodeficiency Virus from People Who Inject Drugs in Indonesia, Ukraine, and Vietnam: HPTN 074.
   Sivay MV, Grabowski MK, Zhang Y, Palumbo PJ, et al · · 2020 · cited 6× · PMID 31794031 · DOI 10.1093/cid/ciz1081
8. Quantifying potentially infectious sharing patterns among people who inject drugs in Baltimore, USA.
   Smith MK, Graham M, Latkin CA, Mehta SH, et al · · 2018 · cited 6× · PMID 30070187 · DOI 10.1017/s0950268818002042